Mutant AAV9 Microdystrophin Vector for Lower-Dose DMD Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors for gene therapy of muscular dystrophy require high doses to achieve effective transduction and gene expression, leading to immune responses and toxicity, necessitating the development of an optimized vector with improved efficiency at lower doses.
Innovation Solution
The optimized AAV vector employs mutant AAV9 vectors, including AAV9K51Q, AAV9N57Q, and AAV9K316Q, with specific post-translational modifications, and a microdystrophin transgene driven by a CBA-Kozak promoter for enhanced transduction and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high initial vector doses of AAV vectors are used to achieve improved outcomes in DMD patients, then transduction efficiency and gene expression levels are improved, but inflammatory myopathy and liver toxicity occur due to host innate immune responses
Solution Approach 1:
The patent modifies the AAV9 capsid structure by introducing point mutations (K51Q, N57Q, K316Q) that alter the viral particle properties. These parameter changes in the capsid structure enable the vector to achieve enhanced transduction efficiency at lower doses while reducing recognition by the host immune system, thereby resolving the contradiction between productivity and harmful immune responses
Solution Approach 2:
The patent creates mutant versions of the AAV9 capsid that replicate the essential functions of the wild-type virus but with modified properties. The mutant capsids copy the gene delivery function while having reduced immunogenicity, allowing effective transduction without triggering severe immune responses that occur with wild-type vectors at high doses
2Reliability
If high vector doses are administered to achieve therapeutic efficacy, then gene expression levels are improved, but liver toxicity occurs due to complement activation
Solution Approach 1:
The patent introduces specific amino acid substitutions in the AAV9 capsid (K51Q, N57Q, K316Q) that change the physical and immunological parameters of the viral particle. These parameter changes reduce complement activation and liver toxicity while maintaining or enhancing therapeutic efficacy at lower vector doses
3Device complexity
If the packaging limit of 5 kb for rAAV virions is constrained, then vector design is simplified, but only highly truncated microdystrophin products can be delivered
Solution Approach 1:
The patent optimizes the microdystrophin transgene construct by modifying promoter elements (using CBA promoter with Kozak sequence) and gene structure to maximize expression within the 5 kb packaging constraint. These parameter changes in the transgene design enable efficient delivery and expression of the truncated dystrophin gene product without exceeding viral capacity
Data Source
AI summary
An optimized AAV vector for gene therapy of muscular dystrophy is provided. The optimized AAV vector includes a plurality of mutant AAV9 vectors and a microdystrophin transgene (p.AAV-CBA-kozak-μDys). The optimized AAV vector demonstrate increased transduction efficiency, gene expression levels, and can potentially achieve optimal therapeutic efficacy in humans at lower vector doses. The optimized AAV vector also demonstrate improved transduction and dystrophin gene expression in a mice model of Duchenne muscular dystrophy.